198 related articles for article (PubMed ID: 1721257)
1. In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use.
Morris RE
Transplant Proc; 1991 Dec; 23(6):2722-4. PubMed ID: 1721257
[No Abstract] [Full Text] [Related]
2. [Mechanism of action of the new immunosuppressants: cyclosporin A, FK 506 and rapamycin].
Rondeau E
Nephrologie; 1992; 13(3):137. PubMed ID: 1379348
[No Abstract] [Full Text] [Related]
3. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions.
Morris RE; Meiser BM; Wu J; Shorthouse R; Wang J
Transplant Proc; 1991 Feb; 23(1 Pt 1):521-4. PubMed ID: 1703698
[No Abstract] [Full Text] [Related]
4. Effects of the immunosuppressive macrolides rapamycin and FK 506 in high responder rats presensitized to major histocompatibility complex antigens.
Propper DJ; Woo J; Macleod AM; Catto GR; Thomson AW
Transplant Proc; 1993 Feb; 25(1 Pt 1):673-4. PubMed ID: 7679837
[No Abstract] [Full Text] [Related]
5. Effect of immunosuppressive drugs (CsA, FK 506, rapamycin) on the kidney microsomal cytochrome P-450 system in the rat.
Yoshimura R; Yoshimura N; Ohmachi T; Nakatani T; Ohyama A; Miyao Y; Yamamoto K; Kishimoto T
Transplant Proc; 1994 Oct; 26(5):2890. PubMed ID: 7524223
[No Abstract] [Full Text] [Related]
6. Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival.
Stepkowski SM; Kahan BD
Transplant Proc; 1991 Dec; 23(6):3262-4. PubMed ID: 1750091
[No Abstract] [Full Text] [Related]
7. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection.
Morris RE; Wu J; Shorthouse R
Transplant Proc; 1990 Aug; 22(4):1638-41. PubMed ID: 1697111
[No Abstract] [Full Text] [Related]
8. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line.
Wang SC; Zeevi A; Jordan ML; Simmons RL; Tweardy DJ
Transplant Proc; 1991 Dec; 23(6):2920-2. PubMed ID: 1721312
[No Abstract] [Full Text] [Related]
9. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function.
Pelekanou V; Trezise AE; Moore AL; Kay JE
Transplant Proc; 1991 Dec; 23(6):3200-1. PubMed ID: 1721408
[No Abstract] [Full Text] [Related]
10. Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin.
Bierer BE
Proc Assoc Am Physicians; 1995 Apr; 107(1):28-40. PubMed ID: 8630742
[No Abstract] [Full Text] [Related]
11. Synergistic interactions of cyclosporine, rapamycin, and brequinar on heart allograft survival in mice.
Stepkowski SM; Tu Y; Chou TC; Kahan BD
Transplant Proc; 1994 Oct; 26(5):3025-7. PubMed ID: 7940952
[No Abstract] [Full Text] [Related]
12. Synergistic activity of the triple combination: cyclosporine, rapamycin, and brequinar.
Stepkowski SM; Kahan BD
Transplant Proc; 1993 Jun; 25(3 Suppl 2):29-31. PubMed ID: 8516939
[No Abstract] [Full Text] [Related]
13. Porcine small bowel transplantation with rapamycin-based induction immunosuppression and short-course cyclosporine or FK 506 therapy.
Cohen DS; Fisher RA; Shapiro JH; Goggins WC; Tawes JW; Mills S; Contos M; Ham JM; Schroeder TJ
Transplant Proc; 1996 Oct; 28(5):2501-5. PubMed ID: 8907923
[No Abstract] [Full Text] [Related]
14. Comparative study of toxicity and efficacy of cyclosporine, cyclosporine G (OG37), FK 506, and rapamycin in BALB/c mice with fitted skin grafts.
Masri MA
Transplant Proc; 1995 Feb; 27(1):366. PubMed ID: 7533412
[No Abstract] [Full Text] [Related]
15. Route of administration determines the efficacy of rapamycin but not the mechanisms of tolerance induced by it in rats.
Lin Y; Rutgeerts O; Waer M
Transplant Proc; 1996 Dec; 28(6):3057. PubMed ID: 8962185
[No Abstract] [Full Text] [Related]
16. Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation.
Ochiai T; Gunji Y; Nagata M; Asano T; Isono K
Transplant Proc; 1991 Dec; 23(6):2718-9. PubMed ID: 1721255
[No Abstract] [Full Text] [Related]
17. Comparison of FK-506, rapamycin, ascomycin, and cyclosporine in mouse models of host-versus-graft disease and heterotopic heart transplantation.
Mollison KW; Fey TA; Krause RA; Thomas VA; Mehta AP; Luly JR
Ann N Y Acad Sci; 1993 Jun; 685():55-7. PubMed ID: 7689812
[No Abstract] [Full Text] [Related]
18. Modes of action of FK506, cyclosporin A, and rapamycin.
Morris R
Transplant Proc; 1994 Dec; 26(6):3272-5. PubMed ID: 7527964
[No Abstract] [Full Text] [Related]
19. Synergistic effect of 3M KCl-extracted donor antigens with cyclosporine or cyclosporine/rapamycin to prolong heart allograft survival in rats.
Hamashima T; Stepkowski SM; Smith S; Kahan BD
Transplant Proc; 1994 Oct; 26(5):3053-5. PubMed ID: 7940960
[No Abstract] [Full Text] [Related]
20. Comparison of rapamycin, RS 61443, cyclosporine, and low-dose heparin as treatment for transplant vasculopathy in a rat model of chronic allograft rejection.
Schmid C; Heemann U; Azuma H; Tilney NL
Transplant Proc; 1995 Feb; 27(1):438-9. PubMed ID: 7879053
[No Abstract] [Full Text] [Related]
[Next] [New Search]
